What US Investors Look for in Life Sciences Companies

Investor perspectives from US-based funds, focused on how early-stage life sciences companies are assessed in practice.

Many European life sciences founders look to the US for capital but investor expectations, incentives, and evaluation frameworks often differ significantly.

In this conversation, US-based investors share how they actually evaluate early-stage life sciences companies and what founders frequently misunderstand when approaching US capital.

This session builds on discussions during the London Life Sciences Week and recent conversations with investors at JP Morgan Healthcare Week in the US, where a recurring theme emerged: many promising life sciences companies struggle not because of weak science, but because of misalignment between how founders pitch and how investors actually evaluate opportunities.

What founders will learn

• How different investor types evaluate opportunities (VC, family offices, corporate venture)• Why many seed & Series A rounds struggle to secure lead investors• What US investors expect from European life sciences companies• When a platform narrative works — and when investors expect assets• How to approach investor targeting before launching a fundraising process

Format

• Moderated investor discussion• Practical frameworks for investor targeting• Audience Q&A

This is a curated discussion designed for founders actively preparing to raise capital.

Duration: 60 minutesFormat: moderated investor discussion + practical frameworks

This session is designed for life sciences and healthcare founders who:

• Founders should ideally be preparing to raise within the next 6–12 months.• Are seed or approaching Series A• Are considering US investors or global capital markets

Priority will be given to founders working in:

biotechtherapeuticstechbio / computational biologymedical deviceshealthcare platforms

Attendance will be limited to maintain a focused discussion.

🎤 SpeakersAnna M. Detert - Principal, Gloucester Ventures

​Pre-seed / seed investor in life sciences tools and advanced diagnostics companies, with focus on precision medicine.

​Anna M. Detert brings 25+ years of experience in life sciences, spanning biopharma, diagnostics, venture capital, and private equity. She was most recently a Partner in KPMG UK's healthcare and life sciences strategy team, based in London. Anna has held consulting and leadership roles at KPMG, Prophet, and Xerox, specialising in commercialisation and growth strategy for pharmaceuticals and diagnostics. She started her career at Bayer Diagnostics (now Siemens) in product development and commercial. She holds an MBA from London Business School and a B.A. in Chemistry & French from Oberlin College.

Stephanie Oestreich - Managing Director, Myeloma Investment Fund

​Stephanie is also on the faculty of MIT, a member of SpringBoard Ventures, an advisor at grIP Venture Studio, to Biognosys (a Bruker company), Invitris, CART company CelineTx and to the drug development and investment company OrangeGrove Bio.

​The Myeloma Investment Fund® (MIF) invests in companies developing innovative therapies and technologies with potential to transform myeloma patient outcomes.

Host: Patrycja Maksymowicz - Commercial Strategist & Founder Sclr Labs

🔒 Limited seats. Approval only.

Sclr Labs & the Innovation Hub